Anydrus Advantage ETF (BATS:NDOW – Get Free Report) was the recipient of a large growth in short interest during the month of April. As of April 30th, there was short interest totaling 5,737 shares, a growth of 146.3% from the April 15th total of 2,329 shares. Based on an average daily trading volume, of 3,917 shares, the short-interest ratio is presently 1.5 days. Approximately 0.3% of the shares of the company are short sold.
Institutional Investors Weigh In On Anydrus Advantage ETF
An institutional investor recently raised its position in Anydrus Advantage ETF stock. Belpointe Asset Management LLC lifted its position in Anydrus Advantage ETF (BATS:NDOW – Free Report) by 7.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,994,920 shares of the company’s stock after buying an additional 134,685 shares during the quarter. Anydrus Advantage ETF makes up approximately 2.0% of Belpointe Asset Management LLC’s portfolio, making the stock its 7th biggest holding. Belpointe Asset Management LLC owned approximately 112.07% of Anydrus Advantage ETF worth $54,998,000 at the end of the most recent reporting period.
Anydrus Advantage ETF Stock Performance
Shares of NDOW stock opened at $29.55 on Friday. The firm’s 50 day moving average is $28.23 and its 200 day moving average is $28.05. Anydrus Advantage ETF has a 12 month low of $24.79 and a 12 month high of $29.63.
Anydrus Advantage ETF Company Profile
The Anydrus Advantage ETF (NDOW) is an exchange-traded fund that mostly invests in target outcome asset allocation. The fund is an actively managed asset allocation fund that seeks capital appreciation and income by holding a broad portfolio of various asset classes from around the world, including ETFs. NDOW was launched on May 14, 2024 and is issued by Anydrus.
Recommended Stories
- Five stocks we like better than Anydrus Advantage ETF
- Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs
- 2 Ways to Play the Big Pharma Patent Cliff
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
Receive News & Ratings for Anydrus Advantage ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anydrus Advantage ETF and related companies with MarketBeat.com's FREE daily email newsletter.
